Literature DB >> 34791555

Optimized Marker System for Early Diagnosis of Breast Cancer.

A M Burdennyy1, E A Filippova2, D S Khodyrev3, I V Pronina2, S S Lukina2, N A Ivanova2, T P Kazubskaya4, V I Loginov2, E A Braga2.   

Abstract

Changes in the methylation levels of 21 microRNA genes in 91 breast cancer samples in comparison with paired samples of histologically unchanged tissue were studied by quantitative methylation-specific PCR. For 19 microRNA genes, a significant increase in the methylation level in tumors in comparison with normal tissues was shown (Mann-Whitney test). When considering the data for breast cancer samples only from patients with clinical stages I and II (59samples), 17 genes with a significantly increased level of methylation were identified. Increased methylation level for 11 genes (MIR124-1, MIR124-3, MIR125B-1, MIR127, MIR129-2, MIR132, MIR137, MIR193a, MIR34B/C, MIR375, and MIR9-1) compared to the paired norm was highly significant (p<0.001, FDR=0.01). The ROC analysis was used to optimize a set of markers for diagnosing breast cancer at the early stages consisting of 4 microRNA genes: MIR125B1, MIR127, MIR1258, and MIR132; the system is characterized by 100% specificity, 85% sensitivity, and AUC=0.924. Importantly, 100% specificity eliminates false positive results. Detection of methylation of at least one of the 4 genes of this set is sufficient to classify the patient's sample as breast cancer.
© 2021. Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  breast cancer; diagnostics; methylation; microRNA genes

Mesh:

Substances:

Year:  2021        PMID: 34791555     DOI: 10.1007/s10517-021-05331-z

Source DB:  PubMed          Journal:  Bull Exp Biol Med        ISSN: 0007-4888            Impact factor:   0.804


  6 in total

Review 1.  MicroRNA epigenetic signatures in human disease.

Authors:  Klara Piletič; Tanja Kunej
Journal:  Arch Toxicol       Date:  2016-08-24       Impact factor: 5.153

Review 2.  Key microRNAs in the biology of breast cancer; emerging evidence in the last decade.

Authors:  Monireh Khordadmehr; Roya Shahbazi; Hamed Ezzati; Farinaz Jigari-Asl; Sanam Sadreddini; Behzad Baradaran
Journal:  J Cell Physiol       Date:  2018-11-13       Impact factor: 6.384

3.  Circulating cell-free DNA in breast cancer: size profiling, levels, and methylation patterns lead to prognostic and predictive classifiers.

Authors:  Maria Panagopoulou; Makrina Karaglani; Ioanna Balgkouranidou; Eirini Biziota; Triantafillia Koukaki; Evaggelos Karamitrousis; Evangelia Nena; Ioannis Tsamardinos; George Kolios; Evi Lianidou; Stylianos Kakolyris; Ekaterini Chatzaki
Journal:  Oncogene       Date:  2019-01-14       Impact factor: 9.867

4.  A methylation-specific and SYBR-green-based quantitative polymerase chain reaction technique for O6-methylguanine DNA methyltransferase promoter methylation analysis.

Authors:  Kirsten Hattermann; H Maximilian Mehdorn; Rolf Mentlein; Susann Schultka; Janka Held-Feindt
Journal:  Anal Biochem       Date:  2008-03-14       Impact factor: 3.365

5.  Marker Systems Based on MicroRNA Gene Methylation for the Diagnosis of Stage I-II Breast Cancer.

Authors:  E A Braga; E A Filippova; V I Loginov; I V Pronina; A M Burdennyi; T P Kazubskaya; M V Fridman; D S Khodyrev; N E Kushlinskii
Journal:  Bull Exp Biol Med       Date:  2019-11-28       Impact factor: 0.804

6.  Assessment of DNA methylation status in early stages of breast cancer development.

Authors:  A Q van Hoesel; Y Sato; D A Elashoff; R R Turner; A E Giuliano; J M Shamonki; P J K Kuppen; C J H van de Velde; D S B Hoon
Journal:  Br J Cancer       Date:  2013-05-07       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.